Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; Advanced Therapy Medicinal Product Technology Development Center (ATMP-TDC), Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
ProGene Technologies Pty Ltd, Sydney, NSW 2113, Australia.
Prog Neurobiol. 2023 Jun;225:102437. doi: 10.1016/j.pneurobio.2023.102437. Epub 2023 Mar 16.
A large number of people worldwide suffer from visual impairment. However, most available therapies rely on impeding the development of a particular eye disorder. Therefore, there is an increasing demand for effective alternative treatments, specifically regenerative therapies. Extracellular vesicles, including exosomes, ectosomes, or microvesicles, are released by cells and play a potential role in regeneration. Following an introduction to EV biogenesis and isolation methods, this integrative review provides an overview of our current knowledge about EVs as a communication paradigm in the eye. Then, we focused on the therapeutic applications of EVs derived from conditioned medium, biological fluid, or tissue and highlighted some recent developments in strategies to boost the innate therapeutic potential of EVs by loading various kinds of drugs or being engineered at the level of producing cells or EVs. Challenges faced in the development of safe and effective translation of EV-based therapy into clinical settings for eye diseases are also discussed to pave the road toward reaching feasible regenerative therapies required for eye-related complications.
全世界有大量的人患有视力障碍。然而,大多数现有的治疗方法都依赖于阻止特定眼部疾病的发展。因此,人们对有效的替代疗法,特别是再生疗法的需求日益增加。细胞释放的细胞外囊泡(包括外泌体、ectosomes 或微泡)在再生中发挥潜在作用。在介绍 EV 的生物发生和分离方法后,本综述概述了我们目前对 EV 作为眼睛中一种通讯范例的了解。然后,我们专注于来源于条件培养基、生物体液或组织的 EV 的治疗应用,并强调了通过装载各种药物或在产生细胞或 EV 的水平上进行工程化来提高 EV 内在治疗潜力的一些最新进展。还讨论了在将基于 EV 的治疗安全有效地转化为眼部疾病的临床应用中所面临的挑战,为实现与眼部相关并发症相关的可行再生疗法铺平道路。